Primary Biliary Cholangitis Therapeutics Market By Drug type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032

Description

List of Tables

According to a new report published by Allied Market Research, titled, "Primary Biliary Cholangitis Therapeutics Market," The primary biliary cholangitis therapeutics market was valued at $683.95 million in 2022, and is estimated to reach $1.4 billion by 2032, growing at a CAGR of 7.1% from 2023 to 2032.

The COVID-19 pandemic caused disruptions in global supply chains, including pharmaceutical manufacturing and distribution. Restrictions on movement, lockdowns, and reduced workforce in manufacturing facilities led to delays in the production and distribution of primary biliary cholangitis (PBC) therapeutics. Therefore, the COVID-19 outbreak had a negative impact on the primary biliary cholangitis therapeutics market.

Primary Biliary Cholangitis Therapeutics Market - IMG1

Market Dynamics

The growth of the primary biliary cholangitis therapeutics market share is driven by the rise in cases of primary biliary cholangitis in Asia-Pacific. For instance, according to the review article "Current understanding of primary biliary cholangitis", published in January 2021, the point prevalence of PBC was 33.8 per 100,000 in the Japanese population. As per the Research Outreach article, in May 2020, over 37,000 people in Japan are estimated to have primary biliary cholangitis (PBC). Rise in the cases of primary biliary cholangitis has resulted in increased demand for primary biliary cholangitis therapeutics.

Furthermore, the pharmaceutical industry continues to invest in research and development efforts to better understand the underlying mechanisms of PBC and develop innovative therapies. This includes exploring new drug targets, conducting clinical trials, and investigating combination therapies. Therefore, the rise in research and development regarding primary biliary cholangitis therapeutics drives the growth of the primary biliary cholangitis therapeutics market size during the forecast period. in June 2021, HighTide Therapeutics ("HighTide"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for non-viral chronic liver diseases, gastrointestinal diseases, and metabolic disorders, announced that the first patient has been dosed in Phase 2 PRONTO-PBC study of HighTide evaluating first-in-class HTD1801 in adult patients with primary biliary cholangitis (PBC).

Moreover, PBC is a chronic condition that requires long-term management. Despite the availability of certain therapies, there is still an unmet need for more effective treatments, particularly for patients who do not respond adequately to existing therapies. This drives the demand for innovative and targeted therapeutics to address the unmet medical needs in PBC. Hence, such factors drive the growth of the primary biliary cholangitis therapeutics market share.

However, lack of awareness regarding primary biliary cholangitis (PBC), early diagnosis of PBC, and limited treatment options are expected to hinder the growth of primary biliary cholangitis therapeutics market. On the contrary, an increase in the adoption of key strategies such as acquisition, product approval, and agreement by key players and advancements in primary biliary cholangitis therapeutics are expected to open new avenues for the growth of the primary biliary cholangitis therapeutics industry across the world during the forecast period.

The COVID-19 pandemic affected the primary biliary cholangitis therapeutics industry in a negative way, such as various healthcare industries were affected due to postponed of non-emergency services. The pandemic has disrupted research activities, including clinical trials, restrictions on patient recruitment and new product development. However, with relaxation in lockdowns and decline in COVID-19 cases, companies have re-started their processes to meet the demand for primary biliary cholangitis therapeutics. In addition, rise in product approvals, and increase in research and development of advanced medicine of primary biliary cholangitis therapeutics drive the growth of primary biliary cholangitis therapeutics market.

In addition, rise in awareness in pharmaceutical companies, and governments regarding supply chain hinderance of pharmaceutical products drives the growth of primary biliary cholangitis therapeutics market. For instance, government agencies in the U.S. and around the globe learned some tough lessons about the pharmaceutical supply chain after the COVID-19 pandemic landed, causing problems and highlighting weaknesses in key areas. In the session of "U.S. Government Investments in Pharmaceutical Manufacturing and Supply Chain and Future Pandemics for today" at the 2022 BIO International Conference, representatives from the U.S. health agencies shared lessons learned from COVID-19, and how government and industry have collaborated to avoid future supply chain crises. Moreover, the U.S. leaders stated that the government has learned since the beginning of the pandemic, steps taken since arrival of COVID-19, and plans the U.S. has put in place to avoid problems in the future. Thus, such trends are expected to bring stabilization in the market, and subsequently witness pre-pandemic growth rate during the forecast period.

Segmental Overview

The primary biliary cholangitis therapeutics market is segmented on the basis of drug type, distribution channel, and region. On the basis of drug type, the market is bifurcated into primary treatment and secondary treatment. The primary treatment segment is further categorized into obeticholic acid, ursodeoxycholic acid, and others (PPARα/PPARδ agonist, and ileal bile acid transport inhibitors). On the basis of distribution channel, it is segregated into hospital pharmacies, drugs stores and retail pharmacies, and online pharmacies. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA).

Key Benefits For Stakeholders:

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the primary biliary cholangitis therapeutics market analysis from 2022 to 2032 to identify the prevailing primary biliary cholangitis therapeutics market opportunity.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the primary biliary cholangitis therapeutics market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global primary biliary cholangitis therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Product Code: A108539

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in cases of primary biliary cholangitis
  - 3.4.1.2. Rise in research and development

3.4.2. Restraints
- 3.4.2.1. Lack of early diagnosis and limited treatment options

3.4.3. Opportunities
- 3.4.3.1. Rise in adoption of key strategies

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DRUG TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Primary Drug
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
- 4.2.4. Primary Drug Primary Biliary Cholangitis Therapeutics Market by Type
4.3. Secondary Drug
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Hospital Pharmacies
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Drugs Stores and Retail Pharmacies
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Online Pharmacies
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country

CHAPTER 6: PRIMARY BILIARY CHOLANGITIS THERAPEUTICS MARKET, BY REGION

6.1. Overview
- 6.1.1. Market size and forecast By Region
6.2. North America
- 6.2.1. Key trends and opportunities
- 6.2.2. Market size and forecast, by Drug type
- 6.2.3. Market size and forecast, by Distribution Channel
- 6.2.4. Market size and forecast, by country
  - 6.2.4.1. U.S.
  - 6.2.4.1.1. Key market trends, growth factors and opportunities
  - 6.2.4.1.2. Market size and forecast, by Drug type
  - 6.2.4.1.3. Market size and forecast, by Distribution Channel
  - 6.2.4.2. Canada
  - 6.2.4.2.1. Key market trends, growth factors and opportunities
  - 6.2.4.2.2. Market size and forecast, by Drug type
  - 6.2.4.2.3. Market size and forecast, by Distribution Channel
  - 6.2.4.3. Mexico
  - 6.2.4.3.1. Key market trends, growth factors and opportunities
  - 6.2.4.3.2. Market size and forecast, by Drug type
  - 6.2.4.3.3. Market size and forecast, by Distribution Channel
6.3. Europe
- 6.3.1. Key trends and opportunities
- 6.3.2. Market size and forecast, by Drug type
- 6.3.3. Market size and forecast, by Distribution Channel
- 6.3.4. Market size and forecast, by country
  - 6.3.4.1. Germany
  - 6.3.4.1.1. Key market trends, growth factors and opportunities
  - 6.3.4.1.2. Market size and forecast, by Drug type
  - 6.3.4.1.3. Market size and forecast, by Distribution Channel
  - 6.3.4.2. France
  - 6.3.4.2.1. Key market trends, growth factors and opportunities
  - 6.3.4.2.2. Market size and forecast, by Drug type
  - 6.3.4.2.3. Market size and forecast, by Distribution Channel
  - 6.3.4.3. UK
  - 6.3.4.3.1. Key market trends, growth factors and opportunities
  - 6.3.4.3.2. Market size and forecast, by Drug type
  - 6.3.4.3.3. Market size and forecast, by Distribution Channel
  - 6.3.4.4. Italy
  - 6.3.4.4.1. Key market trends, growth factors and opportunities
  - 6.3.4.4.2. Market size and forecast, by Drug type
  - 6.3.4.4.3. Market size and forecast, by Distribution Channel
  - 6.3.4.5. Spain
  - 6.3.4.5.1. Key market trends, growth factors and opportunities
  - 6.3.4.5.2. Market size and forecast, by Drug type
  - 6.3.4.5.3. Market size and forecast, by Distribution Channel
  - 6.3.4.6. Rest of Europe
  - 6.3.4.6.1. Key market trends, growth factors and opportunities
  - 6.3.4.6.2. Market size and forecast, by Drug type
  - 6.3.4.6.3. Market size and forecast, by Distribution Channel
6.4. Asia-Pacific
- 6.4.1. Key trends and opportunities
- 6.4.2. Market size and forecast, by Drug type
- 6.4.3. Market size and forecast, by Distribution Channel
- 6.4.4. Market size and forecast, by country
  - 6.4.4.1. Japan
  - 6.4.4.1.1. Key market trends, growth factors and opportunities
  - 6.4.4.1.2. Market size and forecast, by Drug type
  - 6.4.4.1.3. Market size and forecast, by Distribution Channel
  - 6.4.4.2. China
  - 6.4.4.2.1. Key market trends, growth factors and opportunities
  - 6.4.4.2.2. Market size and forecast, by Drug type
  - 6.4.4.2.3. Market size and forecast, by Distribution Channel
  - 6.4.4.3. Australia
  - 6.4.4.3.1. Key market trends, growth factors and opportunities
  - 6.4.4.3.2. Market size and forecast, by Drug type
  - 6.4.4.3.3. Market size and forecast, by Distribution Channel
  - 6.4.4.4. India
  - 6.4.4.4.1. Key market trends, growth factors and opportunities
  - 6.4.4.4.2. Market size and forecast, by Drug type
  - 6.4.4.4.3. Market size and forecast, by Distribution Channel
  - 6.4.4.5. South Korea
  - 6.4.4.5.1. Key market trends, growth factors and opportunities
  - 6.4.4.5.2. Market size and forecast, by Drug type
  - 6.4.4.5.3. Market size and forecast, by Distribution Channel
  - 6.4.4.6. Rest of Asia-Pacific
  - 6.4.4.6.1. Key market trends, growth factors and opportunities
  - 6.4.4.6.2. Market size and forecast, by Drug type
  - 6.4.4.6.3. Market size and forecast, by Distribution Channel
6.5. LAMEA
- 6.5.1. Key trends and opportunities
- 6.5.2. Market size and forecast, by Drug type
- 6.5.3. Market size and forecast, by Distribution Channel
- 6.5.4. Market size and forecast, by country
  - 6.5.4.1. Brazil
  - 6.5.4.1.1. Key market trends, growth factors and opportunities
  - 6.5.4.1.2. Market size and forecast, by Drug type
  - 6.5.4.1.3. Market size and forecast, by Distribution Channel
  - 6.5.4.2. Saudi Arabia
  - 6.5.4.2.1. Key market trends, growth factors and opportunities
  - 6.5.4.2.2. Market size and forecast, by Drug type
  - 6.5.4.2.3. Market size and forecast, by Distribution Channel
  - 6.5.4.3. South Africa
  - 6.5.4.3.1. Key market trends, growth factors and opportunities
  - 6.5.4.3.2. Market size and forecast, by Drug type
  - 6.5.4.3.3. Market size and forecast, by Distribution Channel
  - 6.5.4.4. Rest of LAMEA
  - 6.5.4.4.1. Key market trends, growth factors and opportunities
  - 6.5.4.4.2. Market size and forecast, by Drug type
  - 6.5.4.4.3. Market size and forecast, by Distribution Channel

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

8.1. Intercept Pharmaceuticals, Inc.
- 8.1.1. Company overview
- 8.1.2. Key Executives
- 8.1.3. Company snapshot
- 8.1.4. Operating business segments
- 8.1.5. Product portfolio
- 8.1.6. Business performance
- 8.1.7. Key strategic moves and developments
8.2. Lupin
- 8.2.1. Company overview
- 8.2.2. Key Executives
- 8.2.3. Company snapshot
- 8.2.4. Operating business segments
- 8.2.5. Product portfolio
- 8.2.6. Business performance
- 8.2.7. Key strategic moves and developments
8.3. Zydus Lifesciences Limited
- 8.3.1. Company overview
- 8.3.2. Key Executives
- 8.3.3. Company snapshot
- 8.3.4. Operating business segments
- 8.3.5. Product portfolio
- 8.3.6. Business performance
- 8.3.7. Key strategic moves and developments
8.4. Sun Pharmaceutical Industries Ltd
- 8.4.1. Company overview
- 8.4.2. Key Executives
- 8.4.3. Company snapshot
- 8.4.4. Operating business segments
- 8.4.5. Product portfolio
- 8.4.6. Business performance
8.5. Leeford Healthcare Limited
- 8.5.1. Company overview
- 8.5.2. Key Executives
- 8.5.3. Company snapshot
- 8.5.4. Operating business segments
- 8.5.5. Product portfolio
8.6. Alkem Laboratories Ltd.
- 8.6.1. Company overview
- 8.6.2. Key Executives
- 8.6.3. Company snapshot
- 8.6.4. Operating business segments
- 8.6.5. Product portfolio
- 8.6.6. Business performance
8.7. AMAGEN INDIA LIFE SCIENCES
- 8.7.1. Company overview
- 8.7.2. Key Executives
- 8.7.3. Company snapshot
- 8.7.4. Operating business segments
- 8.7.5. Product portfolio
8.8. GENFIT
- 8.8.1. Company overview
- 8.8.2. Key Executives
- 8.8.3. Company snapshot
- 8.8.4. Operating business segments
- 8.8.5. Product portfolio
- 8.8.6. Business performance
- 8.8.7. Key strategic moves and developments
8.9. Ipsen Pharma
- 8.9.1. Company overview
- 8.9.2. Key Executives
- 8.9.3. Company snapshot
- 8.9.4. Operating business segments
- 8.9.5. Product portfolio
- 8.9.6. Business performance
- 8.9.7. Key strategic moves and developments
8.10. ABC Farmaceutici S.p.a.
- 8.10.1. Company overview
- 8.10.2. Key Executives
- 8.10.3. Company snapshot
- 8.10.4. Operating business segments
- 8.10.5. Product portfolio
- 8.10.6. Key strategic moves and developments